Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

Bibliographic Details
Main Authors:	Rudwaleit, M., Rosenbaum, J. T., Landewé, R., Marzo‐Ortega, H., Sieper, J., van der Heijde, D., Davies, O., Bartz, H., Hoepken, B., Nurminen, T., Deodhar, A.
Format:	Online
Language:	English
Published:	John Wiley and Sons Inc. 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089650/

Similar Items

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
by: Sieper, J., et al.
Published: (2015)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
by: Sieper, J, et al.
Published: (2015)

Active axial spondyloarthritis: potential role of certolizumab pegol
by: Ranatunga, Sriya, et al.
Published: (2014)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
by: Landewé, R, et al.
Published: (2014)

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
by: Mease, P, et al.
Published: (2015)

99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
by: Lambert, Bieke, et al.
Published: (2016)

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
by: Carron, Philippe, et al.
Published: (2016)

Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis: Results of an International Survey
by: van der Heijde, Désirée, et al.
Published: (2014)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
by: Furst, D E, et al.
Published: (2015)

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
by: Schoels, M M, et al.
Published: (2014)

Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort
by: Miranda van Lunteren, et al.
Published: (2018-08-01)

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
by: Mease, P J, et al.
Published: (2014)

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
by: van der Heijde, D, et al.
Published: (2014)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
by: Henry, Alistair I, et al.
Published: (2011)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
by: Colombo, Elisabetta, et al.
Published: (2009)

Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis
by: Rosa, J, et al.
Published: (2010)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
by: Blonski, Wojciech, et al.
Published: (2012)

In vivo pre-activation of monocytes in patients with axial spondyloarthritis
by: Conrad, Kristina, et al.
Published: (2015)

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
by: Combe, Bernard, et al.
Published: (2016)

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
by: Smolen, J S, et al.
Published: (2015)

Cytokine profiles in axial spondyloarthritis
by: Madej, Marta, et al.
Published: (2015)

Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis
by: de Winter, Janneke J., et al.
Published: (2016)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
by: Sieper, J., et al.
Published: (2015)

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
by: Smolen, Josef S., et al.
Published: (2015)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
by: Keystone, Edward, et al.
Published: (2014)

Correlation of Axial Spondyloarthritis with Anxiety and Depression
by: Zou, Qinghua, et al.
Published: (2016)

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature
by: Moisseiev, Elad, et al.
Published: (2014)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
by: Hébuterne, Xavier, et al.
Published: (2013)

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials
by: Nikfar, Shekoufeh, et al.
Published: (2013)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
by: Acosta-Felquer, María Laura, et al.
Published: (2016)

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
by: Curtis, Jeffrey R., et al.
Published: (2015)

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
by: Takeuchi, Tsutomu, et al.
Published: (2016)

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity
by: Pope, Janet, et al.
Published: (2015)

Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling
by: Boyer, Jean Frédéric, et al.
Published: (2016)

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
by: Bykerk, V P, et al.
Published: (2015)

The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
by: Mariette, X, et al.
Published: (2015)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
by: Sieper, Joachim, et al.
Published: (2013)

Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
by: van der Heijde, Désirée, et al.
Published: (2014)

The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist
by: Burgos-Vargas, Ruben
Published: (2012)

The window of opportunity: a relevant concept for axial spondyloarthritis
by: Robinson, Philip C, et al.
Published: (2014)